Literature DB >> 7815502

Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.

A B Kulkarni1, P L Collins, I Bacik, J W Yewdell, J R Bennink, J E Crowe, B R Murphy.   

Abstract

We have studied the immunobiology of respiratory syncytial virus (RSV), a major cause of respiratory tract morbidity in children. As part of these studies, it was previously found that immunization of BALB/c (H-2d) mice with a recombinant vaccinia virus (rVV) which encoded the M2 protein of RSV provided complete protection against infection with RSV. This protection was transient and associated with M2-specific CD8+ T-cell (TCD8+) responses. In this study, we used two approaches to demonstrate that expression of an H-2Kd-restricted nonameric peptide (Ser Tyr Ile Gly Ser Ile Asn Asn Ile) corresponding to M2 residues 82 to 90 is necessary and sufficient to induce protective TCD8+ responses. First, infection of mice with an rVV which encoded the peptide M2Met82-90 induced levels of primary pulmonary TCD8+ and resistance to RSV challenge equivalent to that induced by infection with an rVV which expressed the complete M2 protein. Second, elimination of peptide binding to Kd by the replacement of Tyr with Arg at amino acid position 83 of the full-length protein completely abrogated the ability of an rVV-expressing full-length M2 to induce either M2-specific TCD8+ responses or resistance to RSV infection. These findings demonstrate that the M2(82-90) peptide is the sole determinant of immunity induced in BALB/c mice by the M2 protein and that a remarkably high level of transient resistance to infection with pulmonary virus is associated with TCD8+ responses to a single determinant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815502      PMCID: PMC188700     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters.

Authors:  J Trowsdale; I Hanson; I Mockridge; S Beck; A Townsend; A Kelly
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.

Authors:  M K Spriggs; B R Murphy; G A Prince; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

4.  MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters.

Authors:  E V Deverson; I R Gow; W J Coadwell; J J Monaco; G W Butcher; J C Howard
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

5.  Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein.

Authors:  H C Bodmer; R M Pemberton; J B Rothbard; B A Askonas
Journal:  Cell       Date:  1988-01-29       Impact factor: 41.582

Review 6.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

7.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

8.  The development of Balb/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface.

Authors:  B F Fernie; E C Ford; J L Gerin
Journal:  Proc Soc Exp Biol Med       Date:  1981-05

9.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

10.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

View more
  42 in total

1.  Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; John D Nicewonger; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.

Authors:  F Rodriguez; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract.

Authors:  Peter M Gray; Subhashini Arimilli; Ellen M Palmer; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.

Authors:  L L An; J L Whitton
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.

Authors:  Alexander Kotelkin; Igor M Belyakov; Lijuan Yang; Jay A Berzofsky; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses.

Authors:  Guillermina A Melendi; Dowd Bridget; Ana C Monsalvo; Federico F Laham; Patricio Acosta; Maria Florencia Delgado; Fernando P Polack; Pablo M Irusta
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

8.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infection.

Authors:  Erika L Wissinger; Whitney W Stevens; Steven M Varga; Thomas J Braciale
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

10.  The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.

Authors:  S C Hsu; D M Shaw; M W Steward
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.